Introduction
AliveCor is a Mountain View company founded in 2011 that builds FDA-cleared personal and handheld electrocardiogram devices powered by artificial intelligence. Priya Abani serves as chief executive officer, quoted in AliveCor’s January 13, 2026 press release announcing expanded KAI 12L algorithm clearances. The company’s Kardia product line spans consumer-grade single-lead devices through the Kardia 12L — described as the world’s first AI-powered handheld 12-lead ECG with a single-cable, five-electrode design.
The January 2026 clearance adds five cardiac determinations to KAI 12L — Short PR Interval, Atrial Bigeminy, Ventricular Bigeminy, Left Axis Deviation, and Right Axis Deviation — bringing total FDA-cleared determinations to 39. Brel cites this milestone because AliveCor is expanding diagnostic breadth in a portable form factor adopted by more than 250 U.S. practices per the same release, with growing international deployments.
What the company does
AliveCor captures ECG signals through Kardia hardware and applies KAI AI models to detect arrhythmias, ischemia patterns, and morphology findings within minutes. Kardia 12L acquires eight diagnostic-bandwidth leads through a 0.3-pound battery-operated device — substantially smaller than conventional 12-lead machines — while claiming substantial equivalence to standard ECG analysis solutions in cleared indications. Enterprise offerings include KardiaPro remote monitoring, KardiaStation clinical workflow software, and API integrations for life-sciences trials.
AliveCor reports its devices have recorded more than 350 million ECGs cumulatively per the January 2026 release — a dataset scale supporting iterative AI clearance expansions under FDA review.
Who it serves
AliveCor serves consumers purchasing direct-to-patient devices, employer and payer programs via KardiaComplete, health systems deploying Kardia 12L in outpatient and acute outreach settings, and life-sciences partners running cardiac safety monitoring in trials. The January 2026 release states Kardia 12L identified more than 4,000 instances of myocardial infarction and ischemia since launch — clinical outcomes data hospital buyers weigh alongside device portability.
CMS Medicare payment approval for Kardia 12L in hospital outpatient settings in 2025, following AMA Category III CPT codes in 2024, gives finance committees a reimbursement anchor when comparing portable 12-lead AI against capital-intensive conventional ECG carts.
Veterans Affairs availability and international launches in India, Australia, New Zealand, and Europe referenced on AliveCor’s newsroom index show AliveCor pursuing both U.S. reimbursed outpatient workflows and global direct-to-provider channels beyond consumer retail alone.
Company background
AliveCor was founded in 2011 in Mountain View; David Albert, MD, is widely credited as founder in public company history though Abani leads as CEO since 2019 per AliveCor’s press archive. The company pioneered smartphone-attached personal ECGs before expanding into six-lead and 12-lead handheld systems with successive FDA clearances. AliveCor has pursued patent enforcement against Apple Watch ECG features through ITC proceedings referenced in its newsroom — a legal strategy distinct from pure software AI vendors.
Abani remains the executive voice in major product clearance releases reviewed July 10, 2026, emphasizing AI-powered cardiology in restricted and unconventional care settings where conventional 12-lead machines are impractical.
Product and AI capabilities
KAI 12L applies deep learning to reduced-lead ECG acquisitions, detecting conditions historically requiring full 12-lead machines and trained technician setup. A peer-reviewed study cited in the January 2026 release found Kardia 12L reduces ECG acquisition time by 29% versus conventional systems — an operational metric for throughput-focused clinics.
AliveCor’s sequential determination clearances — 39 total as of January 2026 — reflect a product strategy of expanding AI label breadth on fixed hardware rather than requiring new physical devices for each algorithm addition, similar in concept to predetermined change control approaches used in imaging AI though implemented through AliveCor’s KAI software pipeline.
New rhythm modifiers — Short PR, Atrial Bigeminy, Ventricular Bigeminy — and axis deviations LAD and RAD expand morphology detection beyond arrhythmia classification alone, broadening outpatient screening use cases where axis and conduction abnormalities prompt cardiology referral.
Key developments
2011: AliveCor founded in Mountain View. June 2024: Initial Kardia 12L dual FDA clearance announced. 2024–2025: Category III CPT codes and CMS outpatient payment approval for Kardia 12L. January 13, 2026: Five additional KAI 12L determinations cleared; total reaches 39. April 15, 2026: Kardia 12L European launch announced on AliveCor newsroom index.
AliveCor’s January 2026 release notes Kardia 12L adoption by more than 250 practices with tens of thousands of patients monitored — scale metrics outpatient strategists compare when modeling portable 12-lead deployment versus maintaining conventional cart-based fleets in satellite clinics.
Why it matters
AliveCor matters because it compresses 12-lead diagnostic depth into handheld hardware — a form factor shift with reimbursement milestones that hospital outpatient strategists can model against capital ECG fleet replacement cycles. Compare with ECG-AI software vendor Anumana analyzing standard hospital 12-lead waveforms without proprietary hardware, and consumer-adjacent cardiology AI from HeartFlow in CT-based fractional flow reserve.
Sector context
AliveCor belongs in Brel’s AI in healthcare coverage under AI medical devices and cardiovascular monitoring, related to Anumana ECG-AI algorithms and remote monitoring platforms. Enterprise ambient documentation vendors such as Abridge address clinician workflow burden rather than cardiac electrical signal analysis.
Sources and references
AliveCor KAI 12L FDA clearance press release (January 13, 2026) and leadership page.
- AliveCor — KAI 12L clearance expansion (alivecor.com, January 13, 2026)
- AliveCor — Leadership (alivecor.com)
Reviewed July 10, 2026. Priya Abani is CEO per January 2026 release. Founded 2011 in Mountain View.